GILEAD SCIENCES, INC. is 108.1x more valuable than Monte Rosa Therapeutics, Inc. by market capitalization ($150.83 B vs $1.40 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | GLUE | GILD |
|---|---|---|
| Market cap | $1.40 B | $150.83 B |
| US-listed rank | #2377 | #99 |
| Revenue (latest FY) | $123.67M | $29.44B |
| Net income (latest FY) | -$38.60M | $8.51B |
| Net margin | -31.2% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 352 | 981 |
GILEAD SCIENCES, INC. is 108.1x more valuable than Monte Rosa Therapeutics, Inc. by market capitalization ($150.83 B vs $1.40 B).
In their latest fiscal years, Monte Rosa Therapeutics, Inc. reported $123.67M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Monte Rosa Therapeutics, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.